ClinicalTrials.gg

Program

CD19 CAR-T cells

Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Lupus Erythematosus, Systemic, led by Chongqing Precision Biotech.

Furthest: phase 2, since Feb 13, 20203 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chongqing Precision Biotech32 open or runningphase 2since Feb 13, 2020Feb 13, 2020none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 13, 2020First studies: 2 phase 2 studies in LeukemiaFirst studyNCT04271800, NCT04271410
  2. Dec 11, 2025Phase 1 study in Lupus Erythematosus, SystemicNCT07331467 · 18 planned · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07331467Lupus Erythematosus, Systemic · China1RecruitingJul 202618
NCT04271800Leukemia · China2UNKNOWNDec 31, 202340
NCT04271410Leukemia · China2RecruitingDec 31, 202380

How it is read

Names in the registry

  • “CD19 CAR-T cells”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.